MindWalk (NASDAQ:HYFT) Stock Price Down 2.1% – Should You Sell?

MindWalk Holdings Corp. (NASDAQ:HYFT)’s share price fell 2.1% during trading on Friday . The stock traded as low as $1.39 and last traded at $1.43. 140,227 shares traded hands during trading, a decline of 45% from the average session volume of 256,183 shares. The stock had previously closed at $1.46.

Analyst Ratings Changes

HYFT has been the topic of several recent analyst reports. JonesTrading began coverage on MindWalk in a research note on Thursday, April 16th. They issued a “buy” rating and a $5.00 price target on the stock. UBS Group reiterated a “buy” rating on shares of MindWalk in a report on Friday, March 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of MindWalk in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, MindWalk presently has an average rating of “Moderate Buy” and an average price target of $5.00.

MindWalk Stock Performance

The business’s 50 day moving average price is $1.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.64 and a current ratio of 3.74. The stock has a market cap of $66.01 million, a PE ratio of -7.15 and a beta of 0.83.

Institutional Trading of MindWalk

A number of hedge funds have recently bought and sold shares of HYFT. Bank of Montreal Can lifted its holdings in MindWalk by 81.0% during the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after acquiring an additional 24,500 shares during the period. Renaissance Technologies LLC increased its position in shares of MindWalk by 8.4% during the 4th quarter. Renaissance Technologies LLC now owns 239,080 shares of the company’s stock valued at $435,000 after purchasing an additional 18,600 shares during the last quarter. Jane Street Group LLC increased its position in shares of MindWalk by 147.3% during the 4th quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock valued at $293,000 after purchasing an additional 96,018 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of MindWalk during the 4th quarter worth $91,000. Finally, XTX Topco Ltd raised its stake in shares of MindWalk by 118.6% during the 4th quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the period. 6.70% of the stock is currently owned by institutional investors.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.